481
Views
14
CrossRef citations to date
0
Altmetric
HRT

Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone. A prospective randomized placebo controlled study

, , , , , & show all
Pages 384-387 | Received 06 Dec 2014, Accepted 27 Dec 2014, Published online: 23 Feb 2015

References

  • Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996;51:188–215
  • Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Practice Res Clinic Endocrinol Metab 2013;27:13–24
  • Sitruk-Ware RL. Hormone therapy and the cardiovascular system: the critical role of progestins. Climacteric 2003;6:21–8
  • Corbould A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J Endocrinol 2007;192:585–94
  • Godsland IF, Walton C, Felton C, et al. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 1992;74:64–70
  • Cagnacci A, Ferrari S, Tirelli A, et al. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized study. Contraception 2009;79:111–16
  • Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29–38
  • Preston RA, Alonso A, Panzitta D, et al. Additive effect of drospirenone /17-β-estradiol in hypertensive postmenopausal women receiving enapril. AJH 2002;15:816–22
  • Preston RA, White WB, Pitt B, et al. Effects of drospirenone/17 beta-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. AJH 2005;18:797–804
  • White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17 beta-estradiol, a novel hormone treatment in postmenopausal women with stage I hypertension. Circulation 2005;112:1979–84
  • Cagnacci A, Ferrari S, Napolitano A, et al. Combined oral contraceptive containing drospirenone does not modify 24-h ambulatory blood pressure but increases heart rate in healthy young women: prospective study. Contraception 2013;88:413–17
  • Cagnacci A, De Toni A, Caretto S, et al. Cyclic progestin administration increases energy expenditure and decreases body fat mass in perimenopausal women. Menopause 2006;13:197–201
  • Kupperman HS, Wetchler BB, Blatt MH. Contemporary therapy of the menopausal syndrome. J Am Med Assoc 1959;171:1627–37
  • Hiditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnarie: development and psychometric properties. Maturitas 1996;24:161–75
  • Lindheim SR, Presser SC, Ditkoff EC, et al. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 1993;60:664–7
  • Cagnacci A, Tuveri F, Cirillo R, et al. The effect of transdermal 17-beta-estradiol on glucose metabolism of postmenopausal women is evident during the oral but not the intravenous glucose administration. Maturitas 1997;28:163–7
  • Wilcox JG, Hwang J, Hodis HN, et al. Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein. Fertil Steril 1997;67:57–62
  • Cagnacci A, Piacenti I, Zanin R, et al. Influence of an oral contraceptive containing drospirenone on insulin sensitivity of healthy women. Eur J Obstet Gynecol Reprod Biol 2014;178:48–50
  • Godsland IF, Gangar K, Walton C, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993;42:846–53
  • Duncan AC, Lyall H, Roberts RN, et al. The effect of estradiol and a combined estradiol/progestagen preparation on insulin sensitivity in healthy postmenopausal women. J Clin Endocrinol Metab 1999;84:2402–7
  • Walker RJ, Lewis-Barned NJ, Sutherland WH, et al. The effects of sequential combined oral 17beta-estradiol norethisterone acetate on insulin sensitivity and body composition in healthy postmenopausal women: a randomized single blind placebo-controlled study. Menopause 2001;8:27–32
  • Gambacciani M, Ciaponi M, Cappagli B, et al. Climacteric modifications in body weight and fat tissue distribution. Climacteric 1999;2:37–44
  • Toth MJ, Tchernof A, Sites CK, Poehlman ET. Effect of menopausal status on body composition and abdominal fat distribution. Int J Obes Relat Metab Disord 2000;24:226–31
  • Sørensen MB. Changes in body composition at menopause-age, lifestyle or hormone deficiency? J Br Menopause Soc 2002;8:137–40
  • Sipilä S. Body composition and muscle performance during menopause and hormone replacement therapy. J Endocrinol Invest 2003;26:893–901
  • Cannoletta M, Cagnacci A. Modification of blood pressure in postmenopausal women: role of hormone replacement therapy. Int J Womens Health 2014;6:745–57

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.